SG11202010212RA - Dual atm and dna-pk inhibitors for use in anti-tumor therapy - Google Patents
Dual atm and dna-pk inhibitors for use in anti-tumor therapyInfo
- Publication number
- SG11202010212RA SG11202010212RA SG11202010212RA SG11202010212RA SG11202010212RA SG 11202010212R A SG11202010212R A SG 11202010212RA SG 11202010212R A SG11202010212R A SG 11202010212RA SG 11202010212R A SG11202010212R A SG 11202010212RA SG 11202010212R A SG11202010212R A SG 11202010212RA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- dna
- tumor therapy
- dual atm
- atm
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810359447.6A CN110386932A (zh) | 2018-04-20 | 2018-04-20 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| US201862665296P | 2018-05-01 | 2018-05-01 | |
| PCT/CN2019/083104 WO2019201283A1 (en) | 2018-04-20 | 2019-04-17 | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010212RA true SG11202010212RA (en) | 2020-11-27 |
Family
ID=68283636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010212RA SG11202010212RA (en) | 2018-04-20 | 2019-04-17 | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12187742B2 (enExample) |
| EP (2) | EP4327877A3 (enExample) |
| JP (1) | JP7366996B2 (enExample) |
| KR (1) | KR20210027251A (enExample) |
| CN (2) | CN110386932A (enExample) |
| BR (1) | BR112020021323A2 (enExample) |
| CA (1) | CA3096732A1 (enExample) |
| MA (1) | MA52364A (enExample) |
| MX (1) | MX2020010942A (enExample) |
| SG (1) | SG11202010212RA (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| WO2019201283A1 (en) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| JP7595959B2 (ja) * | 2019-07-30 | 2024-12-09 | エクスラッド セラピューティクス，インコーポレーテッド | 抗腫瘍療法において使用するための二重ａｔｍ及びｄｎａ－ｐｋ阻害剤 |
| CN114746421A (zh) * | 2019-11-19 | 2022-07-12 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| US20230055321A1 (en) * | 2019-11-22 | 2023-02-23 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
| WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| CN114634521A (zh) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| WO2024186805A1 (en) * | 2023-03-06 | 2024-09-12 | Xrad Therapeutics, Inc. | Methods of treating cancer |
| WO2025247391A1 (en) * | 2024-05-31 | 2025-12-04 | Hutchmed Limited | Novel pi3k and/or pikk inhibitors, antibody-drug conjugates comprising the same and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589935A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| AU2007267470B2 (en) | 2006-06-01 | 2012-09-20 | Sanofi-Aventis | Spirocyclic nitriles as protease inhibitors |
| CN105693730A (zh) | 2006-10-19 | 2016-06-22 | 西格诺药品有限公司 | 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途 |
| US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| US8394818B2 (en) | 2008-10-17 | 2013-03-12 | Dana-Farber Cancer Institute, Inc. | Soluble mTOR complexes and modulators thereof |
| JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| BR112013013837A2 (pt) | 2010-12-06 | 2016-09-13 | Piramal Entpr Ltd | derivados de substituição de imidazoquinolina |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR089929A1 (es) | 2012-02-10 | 2014-10-01 | Actelion Pharmaceuticals Ltd | Proceso para manufacturar un derivado de naftiridina |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| CN103936762B (zh) * | 2013-01-17 | 2016-02-24 | 上海汇伦生命科技有限公司 | 吗啉并喹啉类化合物，其制备方法和用途 |
| CN103880844A (zh) | 2014-04-09 | 2014-06-25 | 彭正中 | 一种喹啉酮类新化合物及其制备方法与用途 |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 | ||
| EP3159342B1 (en) * | 2014-06-17 | 2020-08-05 | Cisen Pharmaceutical Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor |
| CN105461711B (zh) * | 2014-06-17 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| EP3159341B8 (en) * | 2014-06-17 | 2020-01-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as pi3k inhibitor |
| CN105461712B (zh) * | 2014-06-17 | 2019-01-29 | 上海嘉坦医药科技有限公司 | 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| EP3277681B1 (de) | 2015-04-02 | 2019-05-08 | Merck Patent GmbH | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
| WO2016186453A1 (en) * | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| EP3405465B1 (en) | 2016-01-20 | 2021-10-13 | Biogen MA Inc. | Irak4 inhibiting agents |
| WO2017162611A1 (en) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| TWI696615B (zh) | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
| GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| MX391410B (es) * | 2018-09-30 | 2025-03-21 | Medshine Discovery Inc | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. |
| JP7595959B2 (ja) | 2019-07-30 | 2024-12-09 | エクスラッド セラピューティクス，インコーポレーテッド | 抗腫瘍療法において使用するための二重ａｔｍ及びｄｎａ－ｐｋ阻害剤 |
-
2018
- 2018-04-20 CN CN201810359447.6A patent/CN110386932A/zh active Pending
-
2019
- 2019-04-17 BR BR112020021323-3A patent/BR112020021323A2/pt not_active IP Right Cessation
- 2019-04-17 SG SG11202010212RA patent/SG11202010212RA/en unknown
- 2019-04-17 CN CN201980040733.9A patent/CN112469720B/zh active Active
- 2019-04-17 KR KR1020207033463A patent/KR20210027251A/ko not_active Withdrawn
- 2019-04-17 JP JP2021506031A patent/JP7366996B2/ja active Active
- 2019-04-17 EP EP23202655.9A patent/EP4327877A3/en not_active Withdrawn
- 2019-04-17 MX MX2020010942A patent/MX2020010942A/es unknown
- 2019-04-17 MA MA052364A patent/MA52364A/fr unknown
- 2019-04-17 CA CA3096732A patent/CA3096732A1/en active Pending
- 2019-04-17 EP EP19787882.0A patent/EP3784671B1/en active Active
-
2020
- 2020-10-19 US US17/074,425 patent/US12187742B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7366996B2 (ja) | 2023-10-23 |
| MX2020010942A (es) | 2021-01-15 |
| CN112469720A (zh) | 2021-03-09 |
| EP4327877A2 (en) | 2024-02-28 |
| CA3096732A1 (en) | 2019-10-24 |
| MA52364A (fr) | 2021-03-03 |
| CN110386932A (zh) | 2019-10-29 |
| EP4327877A3 (en) | 2024-04-24 |
| AU2019254980A1 (en) | 2020-12-03 |
| EP3784671A4 (en) | 2021-11-17 |
| EP3784671A1 (en) | 2021-03-03 |
| JP2021522316A (ja) | 2021-08-30 |
| CN112469720B (zh) | 2024-03-29 |
| BR112020021323A2 (pt) | 2021-01-19 |
| KR20210027251A (ko) | 2021-03-10 |
| US20220315606A1 (en) | 2022-10-06 |
| EP3784671B1 (en) | 2023-10-11 |
| US12187742B2 (en) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289542A (en) | Dual atm and dna-pk inhibitors for antitumor therapy use | |
| SG11202010212RA (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| IL282663A (en) | BT1718 for use in cancer treatment | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| PL3430027T3 (pl) | Peptyd do zastosowania w immunoterapii przeciw niedrobnokomórkowemu rakowi płuc oraz drobnokomórkowemu rakowi płuc | |
| SG10202003124TA (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| SG10201913538VA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| IL276406A (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL284981B2 (en) | Semaphorin-4d antagonists for use in cancer treatment | |
| IL276668A (en) | Thioredoxin reductase inhibitors for use in the treatment of cancer | |
| ZA202000904B (en) | Mpo inhibitors for use in medicine | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| EP3654967A4 (en) | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER | |
| IL285538A (en) | Combined therapies for use in cancer treatment | |
| SG11202111476RA (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer | |
| AU2019254980B2 (en) | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | |
| HK40122782A (zh) | 用於抗肿瘤疗法中的双重atm和dna-pk抑制剂 | |
| ZA201801013B (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| HK40091842A (zh) | 用於癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 | |
| HK40052012A (en) | Usp19 inhibitors for use in therapy | |
| HK40071099A (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer |